Table 3.

Patient characteristics based on ependymal tumor subgroups

	SP-SE	SP-MPE	SP-EPN	PF-SE	PF-EPN-A	PF-EPN-B	ST-SE	ST-EPN-RELA
Number n (%)	5 (4.1)	29 (23.8)	32 (26.2)	24 (19.7)	1 (0.8)	13 (10.7)	14 (11.5)	4 (3.3)
Age, y (median range)	59 (46–73)	43 (18–80)	42 (24–69)	54 (18–79)	42 (42–42)	37 (19–63)	49 (26–73)	37 (26–62)
Sex
Male	2 (40.0)	20 (69.0)	17 (53.1)	23 (95.8)	1 (100.0)	6 (46.2)	11 (78.6)	2 (50.0)
Female	3 (60.0)	9 (31.0)	15 (46.9)	1 (4.2)	0	7 (53.8)	3 (21.4)	2 (50.0)
Karnofsky performance score
<70	0	0	0	1 (4.2)	0	0	0	0
70–80	2 (66.7)	11 (52.4)	10 (41.7)	8 (33.3)	1 (100.0)	3 (25.0)	6 (46.2)	0
90–100	1 (33.3)	10 (47.6)	14 (58.3)	15 (62.5)	0	9 (75.0)	7 (53.8)	3 (100.0)
No data	2	8	8			1	1	1
Surgery
Total	4 (80.0)	25 (86.2)	28 (87.5)	17 (70.8)	0	9 (69.2)	12 (85.7)	3 (75.0)
Subtotal	1 (20.0)	4 (13.8)	3 (9.4)	7 (29.2)	1 (100.0)	4 (30.8)	2 (14.3)	1 (25.0)
Partial	0	0	1 (3.1)	0	0	0	0	0
Histology
Subependymoma	3 (60.0)	0	0	7 (29.2)	0	0	13 (92.9)	0
Myxopapillary ependymoma	0	14 (48.3)	0	0	0	0	0	0
Ependymoma	1 (20.0)	15 (51.7)	32 (100.0)	17 (70.8)	1 (100.0)	7 (53.8)	1 (7.1)	0
Anaplastic ependymoma	1 (20.0)	0	0	0	0	6 (46.2)	0	4 (100.0)
RELA fusion-positive	0	0	0	0	0	0	0	4 (100.0)
WHO 2016 grade
I	3 (60.0)	14 (48.3)	0	7 (29.2)	0	0	13 (92.9)	0
II	1 (20.0)	15 (51.7)	32 (100.0)	17 (70.8)	1 (100.0)	7 (53.8)	1 (7.1)	0
III	1 (20.0)	0	0	0	0	6 (46.2)	0	4 (100.0)
Localization
Intracranial—supratentorial	0	0	0	0	0	0	14 (100.0)	4 (100.0)
Intracranial—infratentorial	1 (20.0)	0	0	24 (100.0)	1 (100.0)	12 (92.3)	0	0
Spinal	4 (80.0)	29 (100.0)	32 (100.0)	0	0	0	0	0
Disseminated	0	0	0	0	0	1 (7.7)	0	0
First-line therapy beyond surgery
RT alone (including cyber knife)	0	2 (6.9)	1 (3.1)	2 (8.3)	0	8 (61.5)	0	2 (50.0)
None	5 (100.0)	27 (93.1)	31 (96.9)	22 (91.7)	1 (100.0%)	5 (38.5)	14 (100.0)	2 (50.0)
Progression
Events, n (%)	0	6 (20.7)	2 (6.3)	3 (12.5)	0	7 (53.8)	1 (7.1)	3 (75.0)
Death
Events, n (%)	0	2 (6.9)	1 (3.1)	2 (8.3)	0	3 (23.1)	2 (14.3)	3 (75.0)